All lobbying filings

FORBES-TATE

FORBES-TATE filed a Q3 report for ALEXION PHARMACEUTICALS, INC. on October 19, 2025, reporting $50,000 in lobbying income.

Lobbying for ALEXION PHARMACEUTICALS, INC. · Biopharmaceutical Company

All filings by FORBES-TATE · Everything ALEXION PHARMACEUTICALS, INC. has reported

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2025

July 1 - Sep 30 · Posted Oct 19, 2025

Income

$50,000

What the client paid this registrant for the period.

Client based in

Massachusetts

Official filing document

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 2

Health Issues

Issues related to healthcare, including drug pricing and Medicare Part D; Issues related to low-volume Diagnosis Related Groups (DRG); Issues related to orphan drug tax credit; Issues related to rare disease; Issues related to the Inflation Reduction Act of 2022 (PL 117-169); Issues related to orphan drugs under the Drug Price Negotiation Program.

Medicare/Medicaid

Issues related to healthcare, including drug pricing and Medicare Part D; Issues related to the Inflation Reduction Act of 2022 (PL 117-169).

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.